Steris Corp. (STE) Position Increased by UBS Asset Management Americas Inc.
UBS Asset Management Americas Inc. increased its position in shares of Steris Corp. (NYSE:STE) by 0.7% during the second quarter, Holdings Channel reports. The firm owned 57,029 shares of the company’s stock after buying an additional 388 shares during the period. UBS Asset Management Americas Inc. owned 0.07% of Steris Corp. worth $3,921,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the stock. American Century Companies Inc. raised its stake in shares of Steris Corp. by 870.8% in the second quarter. American Century Companies Inc. now owns 1,208,491 shares of the company’s stock worth $83,084,000 after buying an additional 1,084,007 shares during the period. Villere ST Denis J & Co. LLC bought a new stake in shares of Steris Corp. during the second quarter worth about $46,505,000. Bank of Montreal Can bought a new stake in shares of Steris Corp. during the second quarter worth about $22,429,000. Royal Bank of Canada raised its stake in shares of Steris Corp. by 109.5% in the first quarter. Royal Bank of Canada now owns 468,134 shares of the company’s stock worth $33,261,000 after buying an additional 244,710 shares during the period. Finally, Channing Capital Management LLC raised its stake in shares of Steris Corp. by 457.1% in the second quarter. Channing Capital Management LLC now owns 273,003 shares of the company’s stock worth $18,769,000 after buying an additional 224,003 shares during the period. Institutional investors and hedge funds own 91.58% of the company’s stock.
Steris Corp. (NYSE:STE) traded up 0.65% on Friday, reaching $73.10. 622,047 shares of the company’s stock traded hands. Steris Corp. has a 52-week low of $61.38 and a 52-week high of $78.77. The firm’s 50-day moving average is $71.34 and its 200 day moving average is $70.24. The stock has a market capitalization of $6.30 billion, a PE ratio of 41.99 and a beta of 1.16.
Steris Corp. (NYSE:STE) last posted its quarterly earnings results on Tuesday, August 9th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.02. The company had revenue of $638.40 million for the quarter, compared to analyst estimates of $639.04 million. Steris Corp. had a net margin of 5.52% and a return on equity of 10.72%. The business’s quarterly revenue was up 45.1% on a year-over-year basis. During the same period last year, the business posted $0.62 EPS. Analysts forecast that Steris Corp. will post $3.90 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 27th. Shareholders of record on Tuesday, August 30th were given a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 1.53%. This is a positive change from Steris Corp.’s previous quarterly dividend of $0.25. The ex-dividend date was Friday, August 26th. Steris Corp.’s dividend payout ratio (DPR) is currently 68.71%.
Several research firms recently weighed in on STE. Zacks Investment Research lowered shares of Steris Corp. from a “hold” rating to a “sell” rating in a research note on Wednesday, September 14th. Northcoast Research upgraded shares of Steris Corp. from a “neutral” rating to a “buy” rating in a research note on Friday, June 3rd.
In other Steris Corp. news, CEO Walter M. Rosebrough, Jr. sold 15,000 shares of the firm’s stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $71.08, for a total value of $1,066,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Daniel A. Carestio sold 2,681 shares of the firm’s stock in a transaction on Friday, August 12th. The stock was sold at an average price of $71.04, for a total transaction of $190,458.24. The disclosure for this sale can be found here. 2.52% of the stock is currently owned by company insiders.
About Steris Corp.
STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Steris Corp. (NYSE:STE).
Receive News & Ratings for Steris Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Corp. and related companies with MarketBeat.com's FREE daily email newsletter.